Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SteraMist™ Makes a Big Difference in Efforts to Fight the Flu in a Delaware Hospital


Posted on: 22 Feb 18

BEVERLY HILLS, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ) is a global company that specializes in plasma science based disinfection/decontamination using its premier Binary Ionization Technology® (BIT™) platform to offer sales and services through the SteraMist™ brand of products. SteraMist™ is a low percentage hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant. SteraMist™ has recently been featured in an article on how one hospital in Delaware is managing to control the spread of the flu virus which has caused many deaths across the state.

Delaware Online, part of the USA Today Network, shared news of record high flu cases in the state and how Saint Francis Healthcare, located in Wilmington, DE, is managing to address the need to control this highly infectious and aggressive flu strain through the use of SteraMist™.

Dr. Sandra Gibney, assistant medical director of Saint Francis Healthcare’s emergency room, refers to this year’s flu as “a virus on steroids” and outlines a variety of containment methods currently being practiced within the hospital to keep patients, staff and visitors as healthy as possible. Dr. Gibney further explains how easy transmission is, not only through touch and shared surfaces, but also through airborne particles and how the hospital is staying ahead of an outbreak is to implement SteraMist™ - referred to as “the mister” - into disinfecting protocols. Because of its nature as an air and surface disinfectant, with proven efficacy against Influenza A, SteraMist™ reduces the spread of infectious viruses and adds an extra level of confidence in hospital staff concerned with managing the spread.

Dr. Gibney states, “It takes care of the airborne, as well as underneath and contact points you normally would not see, it has made a big difference as far as whether or not we can assure that we are not making people who aren’t sick, sick.”

Dr. Halden Shane, TOMI™ CEO, shared, “It is gratifying that Saint Francis, along with many other hospitals across our country and abroad, is finding success with our products. Our mission is to provide technology to secure a safer world and that includes addressing and containing these viruses at a local level. TOMI is proud to offer healthcare facilities an easy and effective disinfection solution.”

About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI’s products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release

MEDIA RELATIONS CONTACT
Juliana deRosa
Executive Administrator
jderosa@tomimist.com

GlobeNewswire
globenewswire.com

Last updated on: 23/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.